Literature DB >> 11346235

Mannitol treatment in central nervous system lupus.

M Eren, E Baskin, A Cila, S Ozen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11346235     DOI： 10.1007/s100670170093

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  7 in total

Review 1.  An overview of the treatment of childhood SLE.

Authors:  E D Silverman; B Lang
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

Review 2.  The central nervous system in systemic lupus erythematosus.

Authors:  M A Khamashta; R Cervera; G R Hughes
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  [Combined use of mannitol and perfluorochemicals in experimental cerebral ischemia].

Authors:  K Mizoi; T Yoshimoto; J Suzuki
Journal:  No To Shinkei       Date:  1983-07

4.  [Experimental study of cerebral protective effect on cerebral ischemia of various antioxidants and other agents. With special reference to the combined treatment of mannitol, vitamin E, dexamethasone and perfluorochemicals].

Authors:  S Fujimoto; K Mizoi; M Oba; J Suzuki
Journal:  No Shinkei Geka       Date:  1984-02

5.  Treatment of acute focal cerebral ischemia with intermittent, low dose mannitol.

Authors:  J R Little
Journal:  Neurosurgery       Date:  1979-12       Impact factor: 4.654

6.  Treatment of intestinal reperfusion injury using antioxidative agents.

Authors:  E Günel; F Cağlayan; O Cağlayan; A Dilsiz; S Duman; M Aktan
Journal:  J Pediatr Surg       Date:  1998-10       Impact factor: 2.545

7.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome.

Authors:  R A Asherson; M A Khamashta; A Gil; J J Vazquez; O Chan; E Baguley; G R Hughes
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.